Amicus Therapeutics Inc (NASDAQ:FOLD) saw an upside of 4.81% to $12.83 after adding $0.59 on Wednesday. The 5-day average trading volume is 1,454,989 shares of the company’s common stock. It has gained $12.83 in the past week and touched a new high 4 times within the past 5 days. An average of 1,935,392 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,274,527.
FOLD’s 1-month performance is 0.07% or -$0.09 on its low of $11.85 reached on 09/25/23. The company’s shares have touched a 52-week low of $9.10 and high of $14.10, with the stock’s rally to the 52-week high happening on 08/09/23. YTD, FOLD has achieved 5.06% or $0.56 and has reached a new high 8 times. However, the current price is down -9.02% from the 52-week high price.
Insider Transactions
FOLD stock investors last saw insider trading activity on Sep 15.Crowley John F (Executive Chairman) most recently sold 6,044 shares at $13.06 per share on Sep 15. This transaction cost the insider $78,964. President & CEO, Campbell Bradley L, sold 18,093 shares at a price of $12.97 on Sep 01. Then, on Sep 01, Executive Chairman Crowley John F sold 6,044 shares at a price of $12.98 per share. This transaction amounted to $78,447.
Valuation Metrics
FOLD stock has a beta of 0.86. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 10.51 while the price-to-book (PB) in the most recent quarter is 33.00.
Amicus Therapeutics Inc’s quick ratio for the period ended June 29 was 2.40, with the current ratio over the same period at 2.72. As well, the company’s long term debt to equity for the quarter ending June 29 was 3.98, while the total debt to equity was 4.05. In terms of profitability, the gross margin trailing 12 months is 87.18%. The trailing 12-month EBITDA margin is -60.47% while for the period ending June 29, Amicus Therapeutics Inc’s operating margin was -36.74%. The firm’s gross profit as reported stood at $290.63 million against revenue of $329.23 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -43.79% to -$43.23 million, while revenue of -$52.93 million was -22.44% off the previous quarter. Analysts expected FOLD to announce -$0.12 per share in earnings in its latest quarter, but it posted -$0.15, representing a -25.00% surprise. EBITDA for the quarter stood at more than -$15.96 million. FOLD stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 618.51 million, with total debt at $452.17 million. Shareholders hold equity totaling $287.12 million.
Let’s look briefly at Amicus Therapeutics Inc (FOLD) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 26 September was 53.63% to suggest the stock is trending Neutral, with historical volatility in this time period at 39.08%.
The stock’s 5-day moving average is $12.29, reflecting a +3.82% or $0.47 change from its current price. FOLD is currently trading -1.08% above its 20-day SMA, +7.76% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -4.84% and SMA200 by+6.68%.
Stochastic %K and %D was 28.13% and 20.25% and the average true range (ATR) pointed at 0.45. The RSI (14) points at 50.91%, while the 14-day stochastic is at 54.95% with the period’s ATR at 0.44. The stock’s 9-day MACD Oscillator is pointing at -0.19 and -0.38 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Amicus Therapeutics Inc (NASDAQ: FOLD), Morgan Stanley launched coverage with an Equal-weight rating. Analysts offering their rating for FOLD stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate FOLD as a “sell,”, while 5 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 7 have offered a “buy” rating.
What is FOLD’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $12.00 and a high of $20.00, with their median price target at $16.50. Looking at these predictions, the average price target given by analysts is for Amicus Therapeutics Inc (FOLD) stock is $16.40.
